Equity · Currency in GBp · Last updated Jun 6, 2026
Avacta Group plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Looking to balance out your exposure to AVCT.L? The ETFs below have the lowest correlation with AVCT.L — they tend to move on their own, which can help reduce risk when AVCT.L drops. The stock ideas table highlights individual companies that behave independently from AVCT.L.
No Diversifiers Found for AVCT.L
We do not have enough correlation history to rank diversifiers for this symbol yet.
Diversification Analysis
Build a portfolio that complements AVCT.L
Add AVCT.L to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.
